[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100482119":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":45,"centralContacts":50,"locations":56,"responsibleParty":133,"collaborators":135,"id":139,"slug":140,"hasResults":141,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":38,"eligibilityCriteria":145,"healthyVolunteers":146,"sex":147,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":38,"studyType":153,"phases":154,"briefSummary":156,"conditions":157,"keywords":38,"overallStatus":73,"whyStopped":38,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Prevention (low-dose aspirin)","EXPERIMENTAL","Patients undergo standard of care breast biopsy for assessment of abnormalities seen on imaging, as well as collection of blood during screening. If cancer is found, patient is taken off study and treatment options are discussed with treating physician.\n\nPatients without a cancer finding on biopsy then receive low-dose aspirin by mouth daily for 42-65 days and undergo collection of blood on study. Patients may undergo breast biopsy as clinically indicated.",[13,14,15,16],"Procedure: Biospecimen Collection","Drug: Low-Dose Aspirin","Other: Questionnaire Administration","Procedure: Biopsy",[18,27,34,39],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Biospecimen Collection","Undergo collection of blood",[9],[24,25,26],"Biological Sample Collection","Biospecimen Collected","Specimen Collection",{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Low-Dose Aspirin","Given PO",[9],[33],"Baby Aspirin",{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Questionnaire Administration","Ancillary studies",[9],null,{"type":19,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"Biopsy","Undergo breast biopsy",[9],[44],"Bx",[46],{"name":47,"affiliation":48,"role":49},"Kathryn J. Ruddy, MD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[51],{"name":52,"role":53,"phone":54,"phoneExt":38,"email":55},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[57,71,86,103,115],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":38},"Mayo Clinic in Arizona","TERMINATED","Scottsdale","Arizona","85259","United States","US",{"type":66,"coordinates":67},"Point",[68,69],-111.89903,33.50921,{"lat":69,"lon":68},{"facility":72,"status":73,"city":74,"state":75,"zip":76,"country":63,"countryCode":64,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Mayo Clinic in Florida","RECRUITING","Jacksonville","Florida","32224-9980",{"type":66,"coordinates":78},[79,80],-81.65565,30.33218,{"lat":80,"lon":79},[83,84],{"name":52,"role":53,"phone":54,"phoneExt":38,"email":55},{"name":85,"role":49,"phone":38,"phoneExt":38,"email":38},"Santo Maimone IV, MD",{"facility":87,"status":73,"city":88,"state":89,"zip":90,"country":63,"countryCode":64,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Indiana University Simon Comprehensive Cancer Center","Indianapolis","Indiana","46202",{"type":66,"coordinates":92},[93,94],-86.15804,39.76838,{"lat":94,"lon":93},[97,101],{"name":98,"role":53,"phone":99,"phoneExt":38,"email":100},"Jessica M","317-278-6706","jlm41@iu.edu",{"name":102,"role":49,"phone":38,"phoneExt":38,"email":38},"Tarah Ballinger, MD",{"facility":48,"status":73,"city":104,"state":105,"zip":106,"country":63,"countryCode":64,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Rochester","Minnesota","55905",{"type":66,"coordinates":108},[109,110],-92.4699,44.02163,{"lat":110,"lon":109},[113,114],{"name":52,"role":53,"phone":54,"phoneExt":38,"email":55},{"name":47,"role":49,"phone":38,"phoneExt":38,"email":38},{"facility":116,"status":117,"city":118,"state":119,"zip":120,"country":63,"countryCode":64,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"University of North Carolina","NOT_YET_RECRUITING","Chapel Hill","North Carolina","27599",{"type":66,"coordinates":122},[123,124],-79.05584,35.9132,{"lat":124,"lon":123},[127,131],{"name":128,"role":53,"phone":129,"phoneExt":38,"email":130},"Joshua Carino","919-445-0472","joshua_carino@med.unc.edu",{"name":132,"role":49,"phone":38,"phoneExt":38,"email":38},"Kristalyn Gallagher, DO",{"type":134,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR",[136],{"name":137,"class":138},"National Cancer Institute (NCI)","NIH","100482119","phase-2-low-dose-aspirin-for-the-prevention-of-postpartum-related-breast-cancer-100482119",false,"NCT05557877","Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer","Targeted Prevention of Postpartum-Related Breast Cancer","Inclusion Criteria:\n\n* PRE-REGISTRATION: Age \\>= 18 years and =\\\u003C 45 years of age\n* PRE-REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research at two timepoints.\n* PRE-REGISTRATION: Had a live birth =\\\u003C 10 years prior to pre-registration\n* PRE-REGISTRATION: Pre-menopausal according to patient report and\u002For clinical determination\n* PRE-REGISTRATION: Provide written informed consent\n* PRE-REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance\n* PRE-REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research\n* REGISTRATION: Age \\>= 18 years and =\\\u003C 45 years of age\n* REGISTRATION: Registration for this study must be completed either =\\\u003C one (1) year after the qualifying pre-registration biopsy is performed for this study or =\\\u003C one (1) year after collection of the archived tissue (for those who did not have a pre-registration biopsy performed after pre-registration for this study)\n* REGISTRATION: Hemoglobin \\>= 9.0 g\u002FdL (obtained =\\\u003C 90 days prior to registration)\n* REGISTRATION: Platelet count \\>= 100,000\u002Fmm\\^3 (obtained =\\\u003C 90 days prior to registration\n* REGISTRATION: Serum creatinine =\\\u003C 2.0 mg\u002Fdl (obtained =\\\u003C 90 days prior to registration)\n* REGISTRATION: Negative pregnancy test done =\\\u003C 15 days prior to registration\n* REGISTRATION: Willing to use contraception while on treatment\n* REGISTRATION: Provide written informed consent\n* REGISTRATION: Ability to complete questionnaire(s) by themselves or with assistance\n* REGISTRATION: Willingness to provide mandatory blood and urine specimens for correlative research\n* REGISTRATION: Willingness to provide mandatory tissue specimens for correlative research\n* REGISTRATION: Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n\nExclusion Criteria:\n\n* PRE-REGISTRATION: History of breast cancer including ductal breast carcinoma in situ (DCIS)\n* PRE-REGISTRATION: Received systemic treatment for any other cancer at any time\n* PRE-REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDS) (no doses within =\\\u003C 5 days prior to pre-registration and no more than four doses within =\\\u003C 30 days prior to pre-registration)\n* PRE-REGISTRATION: Currently taking other agents for the prevention of breast cancer\n* PRE-REGISTRATION: Currently taking anticoagulants\n* PRE-REGISTRATION: Contraindication for aspirin use\n* PRE-REGISTRATION: Known or suspected active breast infection\n* REGISTRATION: Known DCIS or invasive cancer\n* REGISTRATION: No research tissue available from pre-registration biopsy or from archived tissue (collected =\\\u003C 12 months prior to pre-registration)\n* REGISTRATION: Currently taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) (NOTE: no doses within =\\\u003C 5 days prior to registration and no more than four doses within =\\\u003C 30 days prior to registration)\n* REGISTRATION: Co-morbid illnesses\u002Fconditions which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* REGISTRATION: Any contraindication to aspirin use including but not limited to:\n\n  * Bleeding disorders (e.g., hemophilia)\n  * Stomach or intestinal bleeding =\\\u003C 6 months prior to registration\n  * Known allergy to other non-steroidal anti-inflammatory drugs (NSAIDs)\n* REGISTRATION: Currently taking anticoagulants\n* REGISTRATION: Any prior or current malignancy requiring prior or current systemic therapy\n* REGISTRATION: Currently pregnant or planning to become pregnant in the next 90 days\n* REGISTRATION: Post-menopausal:\n\n  * Prior bilateral surgical oophorectomy or\n  * No menses for \\> 1 year with estradiol levels within postmenopausal range, according to institutional standard\n* REGISTRATION: Known or suspected active breast infection",true,"FEMALE","18 Years","45 Years",{"count":151,"type":152},60,"ESTIMATED","INTERVENTIONAL",[155],"PHASE2","This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-inflammatory drug. Giving low-dose aspirin may affect markers of inflammation in blood and tissue and may prevent postpartum related breast cancer.",[158],"Breast Carcinoma","2026-06-15",{"date":161,"type":162},"2026-06-16","ACTUAL",{"date":164,"type":162},"2023-03-09",{"date":166,"type":152},"2027-01-30",{"name":5,"class":6},5]